BRENTWOOD, Tenn. / Oct 24, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced it will issue its third quarter 2024 results after the market closes on Wednesday, November 6, 2024. A conference call will be held the following day, Thursday, November 7, 2024, at 9:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.
A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at https://ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.
To participate in the live teleconference:
United States Live: 1-888-596-4144
International Live: 1-646-968-2525
Access Code: 4437657
To listen to a replay of the teleconference, which will be available through November 14, 2024:
United States Replay: 1-800-770-2030
International Replay: 1-609-800-9909
Access Code: 4437657
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$16.61 |
Daily Volume: | 202,713 |
November 06, 2024 August 14, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB